Paying The Price For Pay-For-Delay: Cephalon's 7-Year Saga
With a $1.2 billion settlement on Thursday ending the Federal Trade Commission's long-running case against Cephalon Inc. for allegedly paying rivals to hold off selling generic versions of the narcolepsy drug...To view the full article, register now.
Already a subscriber? Click here to view full article